Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 933 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How can we diagnose more cancers earlier? July 27, 2021 What to Know About Navigating Your Cancer Care During An Extreme... September 27, 2023 Apple Season is Here! October 1, 2021 Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... July 14, 2023 Load more HOT NEWS A More Treatable Kind of Metastatic Cancer? ΣΤΑΤΙΣΤΙΚΑ EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast
